CASPIAN Trial: Clinical Implications of a 3-Year OS Update of Durvalumab +/- Tremelimumab + Platinum-Etoposide in 1L Treatment of ES-SCLC

360 views
January 29, 2024
0 Comments
Login to view comments. Click here to Login